Protocol summary

Study aim
To determine the effect of prophylactic melatonin administration on the incidence of postoperative delirium in diabetic elderly patients undergoing orthopedic surgery under general anesthesia.
Design
A randomized, double blind, placebo controlled, parallel group clinical trial (Phase 3) with a sample size of 100 patients (50 per group). Simple randomization will be performed using a computer generated random number table.
Settings and conduct
The study will be conducted in the orthopedic surgery wards and the Post Anesthesia Care Unit (PACU) of a single hospital. Participants, surgeons, anesthesiologists, nursing staff, and outcome assessors are blinded to the group assignments. Allocation concealment is maintained using coded medication packages. Delirium assessments will be performed using the Confusion Assessment Method for the Intensive Care Unit (CAM ICU) and Memorial Delirium Assessment Scale (MDAS).
Participants/Inclusion and exclusion criteria
Inclusion criteria: Patients aged 60 years or older with confirmed diabetes mellitus, candidates for elective orthopedic surgery under general anesthesia, Abbreviated Mental Test (AMT) score of 8 or higher, and willing to provide informed consent. Exclusion criteria: History of using medications with known interactions with melatonin (e.g., warfarin), known allergy to melatonin, severe cognitive impairment, or severe hepatic and renal impairment.
Intervention groups
Intervention group: Receiving 5 mg oral melatonin capsules at 21:00 the night before surgery, 30 minutes before anesthesia induction, and at 21:00 for three consecutive nights postoperatively. Control group: Receiving identically appearing placebo capsules at the exact same time points.
Main outcome variables
Incidence of postoperative delirium (based on CAM ICU criteria); severity of postoperative delirium (based on MDAS scale); duration of delirium; length of hospital stay.

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20210222050463N12
Registration date: 2026-10-26, 1405/08/04
Registration timing: prospective

Last update: 2026-10-26, 1405/08/04
Update count: 0
Registration date
2026-10-26, 1405/08/04
Registrant information
Name
Noushin Sarvi Sarmeidani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 61 3390 6395
Email address
sarvi.n@ajums.ac.ir
Recruitment status
Not yet recruiting
Funding source
Expected recruitment start date
2026-11-23, 1405/09/02
Expected recruitment end date
2027-07-24, 1406/05/02
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The Effect of Prophylactic Melatonin Administration on the Incidence of Postoperative Delirium in Diabetic Geriatric Patients Undergoing Orthopedic Surgery under General Anesthesia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Public title
Effect of melatonin on preventing confusion after orthopedic surgery in elderly diabetic patients
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
Patients aged 60 years or older. Patients with a confirmed diagnosis of diabetes mellitus. Candidates for elective orthopedic surgery (total hip replacement, total knee replacement, or fracture repair) under general anesthesia. Abbreviated Mental Test (AMT) score of 8 or higher. Willingness to participate and providing written informed consent.
Exclusion criteria:
History of using medications with known interactions with melatonin (e.g., warfarin, flumazenil, or immunosuppressive agents). Known allergy or hypersensitivity to melatonin. Severe cognitive impairment (AMT score less than 8) or history of severe psychiatric disorders. Severe hepatic or renal impairment. Active alcohol or substance abuse.
Age
From 60 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 100
Randomization (investigator's opinion)
Randomized
Randomization description
This study is a randomized controlled trial. The unit of randomization is individual patients. Eligible patients will be randomly allocated into two groups (intervention and control) using a simple randomization method with a computer-generated random number table. No stratification is applied in this study. The random sequence was generated by an individual independent of the clinical team and principal investigators using a computer software to minimize selection bias. Allocation concealment will be strictly maintained using coded medication packages (identically appearing packages containing either melatonin or placebo).
Blinding (investigator's opinion)
Double blinded
Blinding description
This study is designed as a double-blind clinical trial. All patients, surgeons, anesthesiologists, nursing staff, and outcome assessors are blinded to the group assignments. To ensure this, the control group receives identically appearing placebo capsules (matching in shape, taste, and odor) at the exact same time points as the intervention group. Furthermore, allocation concealment is strictly maintained using coded medication packages. The randomization process is conducted by an individual independent of the clinical team, ensuring that the investigators and clinical staff remain unaware of the group allocations throughout the study. Outcome assessments will be performed by two independent evaluators who are also blinded to the group allocation.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Ahvaz Jundishapur University of Medical Sciences
Street address
Vice Chancellery for Research and Technology, 1st Floor, Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd., Ahvaz
City
Ahvaz
Province
Khouzestan
Postal code
6135715794
Approval date
2026-10-09, 1405/07/17
Ethics committee reference number
IR.AJUMS.REC.1405.342

Health conditions studied

1

Description of health condition studied
Postoperative delirium (POD) is an acute and fluctuating disturbance in attention and cognition that occurs within the first 72 hours after surgery. This study specifically investigates its incidence and severity in elderly diabetic patients following orthopedic surgery under general anesthesia.
ICD-10 code
F05
ICD-10 code description
Delirium due to known physiological condition

2

Description of health condition studied
Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels. This study focuses on elderly patients (aged 60 years and older) with a confirmed diagnosis of diabetes who are at a higher risk of developing postoperative delirium.
ICD-10 code
E11
ICD-10 code description
Type 2 diabetes mellitus

Primary outcomes

1

Description
Incidence of postoperative delirium (defined as a positive diagnosis based on the Confusion Assessment Method for the Intensive Care Unit criteria).
Timepoint
During the first 72 hours postoperatively (assessed twice daily at 8:00 AM and 8:00 PM).
Method of measurement
Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) administered by trained evaluators blinded to group allocation.

Secondary outcomes

1

Description
Severity of postoperative delirium.
Timepoint
On the days when delirium is diagnosed during the first 72 hours postoperatively.
Method of measurement
Memorial Delirium Assessment Scale.

2

Description
Duration of delirium.
Timepoint
During the first 72 hours postoperatively (assessed twice daily).
Method of measurement
Number of days with at least one positive assessment using the Confusion Assessment Method for the Intensive Care Unit.

3

Description
Length of hospital stay.
Timepoint
From the day of surgery until the day of hospital discharge.
Method of measurement
Review of patient medical records and hospital admission and discharge dates.

4

Description
Serum melatonin level.
Timepoint
Preoperatively, 24 hours postoperatively, and 72 hours postoperatively.
Method of measurement
Venous blood sampling and measurement using validated Enzyme-Linked Immunosorbent Assay kits.

Intervention groups

1

Description
Intervention group: Receiving oral melatonin capsules (5 mg) at 21:00 the night before surgery, 30 minutes before anesthesia induction, and at 21:00 for three consecutive nights postoperatively, administered with 15 mL of water.
Category
Treatment - Drugs

2

Description
Control group: Receiving identically appearing placebo capsules (matching in shape, taste, and odor) at the exact same time points (21:00 the night before surgery, 30 minutes before anesthesia induction, and 21:00 for three consecutive nights postoperatively), administered with 15 mL of water.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Imam Khomeini Hospital
Full name of responsible person
Vahid Saidkhani
Street address
Imam Khomeini Educational and Medical Center, Azadegan Street (24 Meteri), Between Sahli Boulevard and Karun River, North of Bagh-e Moein, Ahvaz, Khuzestan, Iran
City
Ahvaz
Province
Khouzestan
Postal code
6193673166
Phone
+98 61 3222 2818
Email
himam@ajums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Abdollah Rafiei
Street address
Golestan Blvd.
City
Ahvaz
Province
Khouzestan
Postal code
6143975617
Phone
+98 916 092 6605
Email
research@ajums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ahvaz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Vahid Saidkhani
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Nursery
Street address
Golestan Blvd
City
Ahvaz
Province
Khouzestan
Postal code
6143975617
Phone
+98 916 092 6605
Email
saidkhani-v@ajums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Nooshin Sarvi-Sarmeydani
Position
Instructor
Latest degree
Master
Other areas of specialty/work
Anesthesiology
Street address
School of Paramedicine, Anesthesiology Department, Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd., Ahvaz
City
Ahvaz
Province
Khouzestan
Postal code
6135715794
Phone
+98 61 3333 0011
Email
nooshinsarvi9192@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Nooshin Sarvi-Sarmeydani
Position
Instructor
Latest degree
Master
Other areas of specialty/work
Anesthesiology
Street address
School of Paramedicine, Anesthesiology Department, Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd., Ahvaz
City
Ahvaz
Province
Khouzestan
Postal code
6135715794
Phone
+98 61 3333 0011
Email
nooshinsarvi@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Not applicable
Title and more details about the data/document
Study Protocol and Statistical Analysis Plan: The full research proposal (protocol) approved by the Ethics Committee, and the detailed statistical analysis plan (including the methods for sample size calculation and multivariate logistic regression) used for this clinical trial.
When the data will become available and for how long
The documents will become available starting 6 months after the publication of the main study results, and will remain available for 5 years.
To whom data/document is available
Academic researchers and healthcare professionals working in recognized universities or research institutions.
Under which criteria data/document could be used
The documents can only be used for non-commercial research purposes and meta-analyses. Applicants must sign a data use agreement ensuring patient confidentiality. All requests will be reviewed and must be approved by the principal investigator and the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences.
From where data/document is obtainable
By sending a formal email request to the principal investigator, Dr. Vahid Saidkhani, at: saidkhani-v@ajums.ac.ir
What processes are involved for a request to access data/document
Applicants must submit a brief research proposal and a signed data use agreement via email. The request will be reviewed by the research team within 2 to 4 weeks. Upon approval, the documents will be shared via a secure file transfer protocol.
Comments
Loading...